AbbVie Inc., one of the world’s largest biopharmaceutical companies, was spun off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. Today, AbbVie CEO Robert A. Michael leads the company’s $61 billion business and a global team of approximately 50,000 employees across more than 175 countries. Appointed CEO in July 2024 and named Chairman of the Board in February 2025, Michael is a 30+ year company veteran who rose from Abbott’s financial development program to architect one of pharma’s greatest strategic pivots — navigating the Humira patent cliff while building a next-generation immunology franchise around Skyrizi and Rinvoq that generated $25.9 billion combined in 2025.
(Suggested: Pfizer CEO Email & Net Worth – Albert Bourla Salary)
Robert A. Michael – Quick Facts
AbbVie Competitors
AbbVie operates in the highly competitive global biopharmaceutical industry. The key competitors of AbbVie include:
- Johnson & Johnson (Innovative Medicine) – diversified pharma and medtech leader
- Merck & Co. – Keytruda franchise dominates oncology
- Pfizer – broad portfolio across oncology, vaccines, and specialty care
- Roche / Genentech – oncology and immunology biologics leader
- AstraZeneca – fast-growing oncology and rare disease portfolio
- Eli Lilly – GLP-1 diabetes/obesity franchise driving explosive growth
- Amgen – biosimilars and inflammation therapeutics
- Bristol-Myers Squibb – immuno-oncology and cardiovascular
(Related: Merck CEO Email & Net Worth – Robert Davis Salary)
Robert A. Michael Net Worth 2026 – AbbVie CEO Salary
As of 2026, Robert A. Michael net worth is estimated at approximately $20–25 million USD, based on his disclosed AbbVie stock holdings in SEC filings and accumulated compensation. Michael directly holds approximately 98,645 shares of AbbVie stock (ABBV), valued at roughly $23 million at current share prices around $234. With AbbVie’s stock appreciating significantly since his tenure as CEO began, his net worth has grown substantially.
AbbVie CEO Compensation Breakdown (FY2024)
AbbVie Net Worth 2026 – Is AbbVie Profitable?
Yes, AbbVie is highly profitable. Under CEO Robert A. Michael, AbbVie delivered record net sales in 2025 despite the ongoing impact of Humira’s loss of U.S. exclusivity, demonstrating the strength of its diversified growth platform.
AbbVie Financial Summary (FY2025 vs. FY2024)
(Recommended: Eli Lilly CEO Email & Net Worth – Dave Ricks Salary)
AbbVie CEO Email Address | Robert A. Michael Contact
Below are the official contact details and social media profiles for AbbVie CEO Robert A. Michael:
Career & Education – Company, University, & College
Robert A. Michael’s career spans more than 30 years within the Abbott/AbbVie ecosystem. He is one of the rare pharma CEOs who spent his entire career at a single company, rising from an entry-level financial development program to the chairman and CEO role. Below is his complete career timeline:
Robert A. Michael Career Timeline
Michael joined Abbott Laboratories’ financial development program early in his career and quickly advanced through various controller and finance leadership positions across the company’s diverse businesses, including pharmaceuticals, aesthetics, diagnostics, diabetes care, and nutrition. This broad cross-functional exposure gave him a comprehensive understanding of the healthcare industry that few executives possess.
When AbbVie was spun off from Abbott in 2013, Michael transitioned to the new company and was named AbbVie’s first-ever Chief Financial Officer in 2018. In this role, he was the key architect of AbbVie’s strategy to diversify beyond Humira, including the landmark $63 billion acquisition of Allergan in 2019 — one of the largest pharmaceutical deals in history.
He was subsequently promoted to Vice Chairman in 2021, then President in 2022 and President and COO in 2023, before being unanimously selected by the Board to succeed Richard Gonzalez as CEO effective July 1, 2024. In February 2025, he was additionally appointed Chairman of the Board.
(Related: AstraZeneca CEO Email & Net Worth – Pascal Soriot Salary)
Education
Robert A. Michael Wiki – Age, Family, & More
AbbVie CEO Robert A. Michael (age 54, born approximately 1970) is based in the Chicago, Illinois area near AbbVie’s North Chicago headquarters. He is a Certified Public Accountant (CPA) and is known as a detail-oriented finance executive who rose to the top through operational excellence and deep institutional knowledge. His elevation from CFO to CEO represents one of the clearest finance-to-CEO transitions in major pharma.
Michael keeps his personal and family life private, and details about his spouse and children are not publicly available in corporate filings or media profiles. He is known for his reserved, analytical leadership style — a stark contrast to his predecessor Richard Gonzalez, who was known as a more public-facing CEO.
Leadership & Key Achievements
- Humira Patent Cliff Navigation – Architected AbbVie’s strategy to survive the loss of Humira (which generated $21 billion at its peak), successfully replacing lost revenue with next-generation drugs
- $63 Billion Allergan Acquisition – Led the financial structuring of one of pharma’s largest-ever deals, expanding AbbVie into aesthetics (Botox) and neuroscience
- Skyrizi & Rinvoq Launch – Championed the growth of AbbVie’s replacement immunology franchise, which generated $25.9 billion combined in 2025
- Record Revenue – Delivered record net sales of $61.2 billion in his first full year as CEO (2025)
- AbbVie’s First CFO – Served as the company’s inaugural Chief Financial Officer from 2018, building the financial infrastructure of the post-Abbott entity
- 30+ Year Company Veteran – One of the longest-tenured CEOs in big pharma, having spent his entire career within the Abbott/AbbVie ecosystem
About AbbVie Inc.
AbbVie Inc. is an American biopharmaceutical company headquartered in North Chicago, Illinois. Formed in 2013 as a spin-off from Abbott Laboratories, AbbVie focuses on immunology, oncology, neuroscience, and aesthetics. The company trades on the New York Stock Exchange under the ticker symbol ABBV and is a component of the S&P 100 and Dow Jones Industrial Average.
AbbVie Key Product Portfolio
AbbVie operates in over 175 countries and employs approximately 50,000 people worldwide. The company has a market capitalization of approximately $410 billion as of early 2026, making it one of the 30 most valuable publicly traded companies in the world.
Frequently Asked Questions (FAQ)
Who is the current CEO of AbbVie?
The current CEO of AbbVie is Robert A. Michael, who was appointed Chief Executive Officer on July 1, 2024, and additionally named Chairman of the Board in February 2025. He succeeded Richard A. Gonzalez, who led AbbVie since its 2013 spin-off from Abbott Laboratories.
What is Robert A. Michael’s net worth in 2026?
As of 2026, Robert A. Michael’s net worth is estimated at $20–25 million USD, based on his disclosed AbbVie stock holdings of approximately 98,645 shares and accumulated compensation over his 30+ year career at Abbott/AbbVie.
What is AbbVie CEO’s salary?
Robert A. Michael’s total compensation for fiscal year 2024 was approximately $18.5 million, including a $1.6 million base salary, $4.59 million annual bonus, $7.9 million in stock awards, $1.9 million in stock options, and $482,000 in other compensation. Over 91% of his pay is performance-based.
What is AbbVie CEO’s email address?
AbbVie CEO Robert A. Michael can be contacted at [email protected]. The company headquarters phone number is (847) 932-7900, located at 1 North Waukegan Road, North Chicago, IL 60064. He is also available on LinkedIn.
What happened to Humira?
Humira lost U.S. patent exclusivity in 2023, causing its revenue to fall from a peak of $21 billion to $4.5 billion in 2025. AbbVie successfully replaced this lost revenue with next-generation immunology drugs Skyrizi ($17.6B in 2025) and Rinvoq ($8.3B in 2025), which generated $25.9 billion combined.
Is AbbVie a profitable company?
Yes, AbbVie is highly profitable. In fiscal year 2025, the company reported record net revenues of $61.2 billion, an 8.6% increase year-over-year. AbbVie has a market capitalization of approximately $410 billion and is a component of the Dow Jones Industrial Average and S&P 100 index.
Article last updated:February 2026March 4, 2026
Disclaimer: All information presented in this article has been compiled from publicly available sources, including SEC filings, official company press releases, AbbVie annual reports, and reputable news outlets. Net worth figures are estimates based on disclosed stock holdings and may vary by source. This content is provided for informational purposes only and does not constitute financial or investment advice.